Enitociclib
As of the edition of 20 October 2026, Enitociclib is a small molecule: stopped in 2023; acts on CDK9.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2023
- Kind
- Small molecule
- Registered trials
- 4, 1 stopped early
- Disease areas
- Cancer; Blood and lymph; Immune system; Digestive system; Infections; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route A because of this drug.
Companies on route A for this drug
In the product2 companies are on route A because of Enitociclib.
See the 2 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CDK9 | Cyclin-dependent kinase 9 | P50750 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 3 | 2 | 0 | 1 |
| Phase 2 | 1 | 1 | 0 | 0 |
| All trials | 4 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Vincerx Pharma | Lead sponsor of trials | 2016 to now |
| Bayer | Lead sponsor of trials | 2016 to now |